Optometrists in Granite Bay, CA Accepting Medicare
5 Optometrists found. Showing 1 - 5
 Kevin G. Lockhart, O.d., Inc Optometrist Medicare: Medicare Enrolled Practice Location: 5520 Douglas Blvd, Suite 110, Granite Bay, CA 95746 Phone: 916-791-5490 Fax: 916-791-3099 |
 Dr. Richard A Borghi, OD Optometrist - Occupational Vision Medicare: Not Enrolled in Medicare Practice Location: 6049 Douglas Blvd, Suite 23, Granite Bay, CA 95746 Phone: 916-791-3388 Fax: 916-791-1124 |
Granite Bay Vision Care Optometry Optometrist Medicare: Medicare Enrolled Practice Location: 5520 Douglas Blvd Ste 110, Granite Bay, CA 95746 Phone: 916-791-5490 |
Richard A Borghi, Od, Apc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 6049 Douglas Blvd, Suite 23, Granite Bay, CA 95746 Phone: 916-791-3388 Fax: 916-791-1124 |
Dr. Kevin Gregory Lockhart, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 5520 Douglas Blvd, Suite 110, Granite Bay, CA 95746 Phone: 916-791-5490 Fax: 916-791-3099 |
News Archive
Researchers establish link between higher providers' industry payments and increased healthcare costs
A multi-disciplinary research team at Indiana Univerity has established an association between higher industry payments to health care providers and higher medical and drug costs for patients.
OXiGENE reports consolidated net loss of $11.0M for first-quarter 2010
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ended March 31, 2010, and presented an update on recent clinical and corporate progress.
Glycolipids play an important role in intercellular signalling
In a new study, scientists at the University of Copenhagen show that a specific type of carbohydrate plays an important role in the intercellular signalling that controls the growth and development of the nervous system. In particular, defects in that carbohydrate may result in the uninhibited cell growth that characterizes the genetic disease neurofibromatosis and certain types of cancer.
Merck, Idera Pharmaceuticals extend their vaccine research collaboration
Idera Pharmaceuticals, Inc. today announced that Merck & Co., Inc., through an affiliate, has extended its research collaboration with Idera for a fourth year. In December 2006, the companies entered into an exclusive license and research collaboration agreement to research, develop, and commercialize vaccine products containing the Company's investigational agonist compounds targeting Toll-like Receptors (TLRs) 7, 8, and 9 in the fields of oncology, infectious diseases, and Alzheimer's disease.
› Verified 3 days ago
Chiropractors
Physical Therapists
Optometrists
Speech-Language Pathologists
Occupational Therapists
Podiatrists